

GCP Questions, FDA Answers

Table of Contents

Introduction	
Applicable Trials and ClinicalTrials.gov	3
Corrective Action	13
Data Collection and Management.....	17
Financial Disclosure and Reimbursement	35
General GXP Questions	37
Guidances and Regulations.....	39
Independent Review Boards	43
Informed Consent.....	47
Investigational New Drugs	53
Investigators	63
Laboratories	87
Monitoring and Oversight.....	93
Noninterventional Trials	97
Protocols	103
Recruitment and Enrollment.....	109
Site Management	117
Subjects.....	123
Testing.....	135
Trial Management.....	139
Appendices.....	147
A. ICH E 6 – Good Clinical Practice	
B. NIH Elaboration on Definitions of Responsible Party and Applicable Clinical Trial	
C. FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND – Frequently Asked Questions	
D. Investigational New Drug Applications (INDs) — Determining Whether Human Research Studies Can Be Conducted Without an IND	
E. Investigator Responsibilities – Protecting the Rights, Safety and Welfare of Study Subjects	

- F. IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed
 - G. Instructions for Completion of Form FDA 3674 – Certification of Compliance
 - H. IRB Continuing Review after Clinical Investigation Approval
 - I. Oversight of Clinical Investigations – A Risk-Based Approach to Monitoring
 - J. FDA Inspections of Clinical Investigators
 - K. Computerized Systems Used in Clinical Trials
 - L. Electronic Source Data in Clinical Investigations
 - M. Use of Electronic Informed Consent in Clinical Investigations – Questions and Answers
 - N. Part 11, Electronic Records; Electronic Signatures – Scope and Application
 - O. Computerized Systems Used in Clinical Investigations
 - P. Informed Consent Information Sheet
 - Q. CPGM 7348.811 – Clinical Investigators and Sponsor-Investigators
 - R. Financial Disclosure by Clinical Investigators
 - S. Charging for Investigational Drugs under an IND – Questions and Answers
 - T. PAT – A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance
 - U. Quality Systems Approach to Pharmaceutical cGMP Regulations
 - V. FDA Form 3674 – Certification of Compliance
 - W. Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable
 - X. CPGM 7348.810 – Sponsors, Contract Research Organizations and Monitors
 - Y. Guideline on the Preparation of Investigational New Drug Products (Human and Animal)
 - Z. FDA Form 1572 – Statement of Investigator
 - AA. Frequently Asked Questions – Statement of Investigator (Form FDA 1572)
 - BB. Establishment and Operation of Clinical Trial Data Monitoring Committees
 - CC. Safety Reporting Requirements for INDs and BA/BE Studies – Small Entity Compliance Guide
 - DD. Investigational New Drug Applications Prepared by Sponsor-Investigators
 - EE. The Applicability of Good Laboratory Practice in Premarket Device Submissions: Questions and Answers
 - FF. Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff
 - GG. ICH E3 – Structure and Content of Clinical Study Reports: Questions and Answers
 - HH. Process Validation: General Principles and Practices
 - II. Adverse Event Reporting to IRBs – Improving Human Subject Protection
 - JJ. ICH E8 – General Considerations for Clinical Trials
 - KK. ICH E9 – Statistical Principles for Clinical Trials
 - LL. Questions and Answers on Informed Consent Elements, 21 CFR 50.25(c)
-